Integrantes do Ministério da Saúde realizaram uma visita técnica na última segunda-feira, 2 de março, no Delphina Aziz, em Manaus, para análise de maturidade das UTIs selecionadas pelo projeto UTI Int ...
Donald Trump concorda em dialogar com o novo líder interino do Irã, Alireza Arafi, após a morte do aiatolá Ali Khamenei em ataques dos EUA e Israel. O Irã acusa Trump de cruzar uma “linha vermelha ...
O secretário do Conselho Supremo de Segurança Nacional do Irã, Ali Larijani, fez essas declarações em entrevista à estatal IRIB TV, horas após o país confirmar a morte do seu líder supremo, Ali ...
Aziz Nasirzadeh começou sua trajetória militar durante a Guerra Irã-Iraque (1980-1988) e consolidou sua carreira como piloto ...
Novo Nordisk CEO Mike Doustdar says the company is aiming to capture around 15 million new patients when Medicare starts covering obesity treatments. Doustdar said he doesn't expect Medicare access to ...
Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving patients and putting their health at risk” by selling compounded versions of ...
Novo Nordisk A/S said it’s suing Hims & Hers Health Inc. for making knockoffs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill. Hims is breaching the ...
Hims & Hers (HIMS) on Monday called a patent lawsuit filed by Novo Nordisk (NVO) over IP rights linked to the Danish drugmaker’s weight loss therapy, semaglutide, “a blatant attack” targeting ...
Novo shares rise 5% after Hims scraps $49 weight‑loss pill FDA signals broader crackdown on compounded GLP-1 drugs Hims pulled its semaglutide-based pill after pushback Hims says lawsuit attacks ...
During the first six months of Maziar Mike Doustdar's tenure as Novo Nordisk's CEO, the company enjoyed a run of positive momentum highlighted by the launch of its Wegovy pill and a recent stock-price ...
The once high-flying Danish drugmaker has struggled to fend off rivals in the weight-loss industry, especially Eli Lilly, which gave a much rosier outlook to investors. By Eshe Nelson Novo Nordisk, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results